aficamten
Myqorzo · ATC code 3553
Also known as: Afikamten
- Key facts
- Active substance
- aficamten
- ATC code
- 3553
- Authorisation
- centrally authorised across the EU (EMA)
- Dosage forms
- MYQORZO 5 mg film-coated tablets / MYQORZO 10 mg film-coated tablets / MYQORZO 15 mg film-coated tablets
- Marketing authorisation holder
- Cytokinetics (Ireland) Limited
- Information as of
- 2026-10-28
Key facts
Aficamten is a cardiac myosin inhibitor that reduces cardiac contractility. It is used in adults with symptomatic obstructive hypertrophic cardiomyopathy.
What it is used for
- Treatment of symptomatic (NYHA class II–III) obstructive hypertrophic cardiomyopathy (oHCM) in adults.
Dosing
- Myqorzo (film-coated tablets): starting dose 5 mg once daily; a starting dose of 10 mg should be considered for patients with LVOT gradient ≥ 100 mmHg.
- Increase every 2 to 8 weeks by 5 mg until a maintenance dose or the maximum dose of 20 mg once daily is reached; the maintenance dose is individualised based on LVEF and Valsalva LVOT gradient.
- Assess LVEF by echocardiography before starting; initiation or up-titration is not recommended with LVEF < 55%. With LVEF < 50% decrease the dose; with LVEF < 40% interrupt treatment for at least 7 days.
- Once the maintenance dose is established, assess LVEF and LVOT gradient every 6 months (every 3 months if LVEF ≥ 50% to < 55%).
- Mild to moderate renal or hepatic impairment: no adjustment; no dose recommendation in severe impairment (not studied). No adjustment for patients aged 65 years and older.
Contraindications
- Hypersensitivity to the active substance or to any of the excipients.
- Moderate CYP2C9 inhibitors that are also moderate-to-strong inhibitors of CYP2D6 or CYP3A (e.g. adagrasib, more than a single dose of fluconazole).
- Strong CYP3A4 inducers that are also moderate CYP2C9 inducers: rifampicin and St John's wort.
Important warnings
- Aficamten reduces LVEF; heart failure due to systolic dysfunction can occur. Clinical status and LVEF should be assessed before and regularly during treatment.
- Severe intercurrent illness (e.g. serious infection) or new arrhythmia (e.g. atrial fibrillation) increases the risk; additional monitoring should be considered.
- Arrhythmia, dyspnoea, chest pain, fatigue, leg oedema or rising NT-proBNP may be signs of heart failure.
- Medicines inhibiting several elimination pathways (e.g. fluconazole, voriconazole, fluvoxamine) or strong CYP2C9 inhibitors can increase aficamten levels.
- Stopping treatment may lead to recurrence of HCM symptoms; gradual dose reduction may attenuate this.
Side effects
- Most commonly reported: dizziness (4.2%), systolic dysfunction defined as LVEF < 50% (3.5%), palpitations (7%) and hypertension (7.7%).
Interactions
- Starting or increasing negative inotropes (e.g. non-dihydropyridine calcium channel blockers, disopyramide): close supervision and LVEF monitoring.
- Aficamten is mainly metabolised by CYP2C9 and to a lesser extent by CYP2D6 and CYP3A; inhibitors and inducers of these enzymes can change exposure – see the full text.
Pregnancy and breastfeeding
- Women of childbearing potential have to use effective contraception during treatment.
- Should not be used during pregnancy unless the clinical condition of the woman requires treatment with aficamten.
Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.
Common questions – ask Medelix
For patients
Package leaflet, verbatim
This product has no separate US patient information.
Authorisation and brand names by country
Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.
EU – centrally authorised (all member states)
- MyqorzoCytokinetics (Ireland) Limited · EMEA/H/C/006228
Source: European Medicines Agency (EMA), product information
Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.
Another question about this substance?
Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.
Sources
- European Medicines Agency. Myqorzo – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/myqorzo-epar-product-information_en.pdf
Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error
Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.